Healthcare (Substance Abuse)

This Senate Resolution (SR 32) urges New Jersey's State Boards of Medical Examiners, Dentistry, Nursing, and Pharmacy to require ongoing training for healthcare professionals on opioid pain medication. The resolution specifically calls for continuing education covering responsible prescribing practices, non-opioid pain management alternatives, and recognizing signs of opioid misuse or addiction. It applies to all prescribers (like doctors, dentists, pharmacists) and relevant non-prescribers (such as nurses) who interact with patients on opioids. The resolution is non-binding and recommends these requirements remain in effect for two license renewal cycles, unless extended by the boards.

This New Jersey bill (S 349) updates licensing rules for residential substance use treatment facilities. It requires applicants to submit independent financial audits (paid by the applicant) and criminal background checks for owners/principals (denial if fraud/dishonesty convictions are found). Facilities must undergo annual unannounced inspections and file detailed annual reports on incidents like injuries, outbreaks, or staff misconduct. The bill also mandates transparency for funding applications, requiring disclosure of financials, ownership, and staff details to the Department of Health. These changes directly affect facilities seeking or maintaining licenses to operate in New Jersey.

S 2893 requires landlords to obtain written approval from New Jersey's Department of Health (DOH) before evicting or interfering with hospital operators or their successors. This applies to any "adverse possessory action," such as lease termination or removal from hospital property, directly affecting hospital operators, landlords, and the DOH. The bill mandates DOH approval for such actions based on "just cause," with violations resulting in civil penalties up to $1 million, license suspensions, and potential criminal charges for actions causing hospital closures. It also ensures hospitals can seek financial recovery for revenue losses due to unauthorized actions.

SJR 31 establishes the New Jersey Pharmacogenomics Commission to study how a person's genetic makeup affects medication effectiveness and safety (pharmacogenomics). The 13-member commission, appointed by the Governor and legislative leaders, will examine costs, benefits for patients and providers, applications like opioid crisis response, and potential reductions in adverse drug events. It must hold public hearings in northern and southern New Jersey within six months of forming and submit a final report to the Governor and Legislature within six months of its organization. The commission expires after submitting this report, which will inform potential future policy decisions. This is a study commission only - no new laws or funding are created by the bill.